Clinical trial · Observational
Single Photon Emission Computed Tomography/Computed Tomography With Pentavalent 99mTc Dimercaptosuccinic Acid in Patients With Brain Glioma; Correlation With IDH Mutation
NCT05593809CI-TRIAL-00061669unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to evaluate the correlation between degree of 99mTc-DMSA (V) uptake at SPECT/CT and IDH mutation in patients with brain glioma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Glioma | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| SPECT with pentavalent 99mTc DMSA | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- degree of 99mTc-DMSA (V) uptake at SPECT/CT
- timeFrame
- Baseline
- description
- measured by calculating quantitative index of 99mTc-DMSA (V) uptake at SPECT/CT as a biomarker for IDH mutation expression
Secondary outcomes (1)
- measure
- IDH mutation
- timeFrame
- Baseline
- description
- measured by immunohistochemistry technique using the anti-IDH antibody
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Patients with a pathologically proven glioma. • patients conscious to provide informed consent Exclusion Criteria: * Pregnant women. * severely ill patients and those with disturbed conscious level, * patients who were judged that they cannot lie down comfortably without movement for at least 20 min
References
Publications (0)
Data not yet available
No reference posted for this study.